| 产品描述: | BGB-16673 (BGB-16673; BTK-IN-29) is an orally active, selectively chimeric degradation activator compound (CDAC), targeting BTK (IC50=0.69 nM). BGB-16673 ligates BTK to E3 ubiquitin ligase, causing BTK to undergo polyubiquitination, which is then recognized and degraded by the proteasome, thereby exerting efficient BTK degradation activity. BGB-16673 can be used in the research of B-cell malignancies such as chronic lymphocytic leukemia, small lymphocytic lymphoma, and mantle cell lymphoma. |
| 体内研究: |
Catadegbrutinib (compound 14) |
| 参考文献: |
1. Hexiang Wang, et al. Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use. WO2021219070A1. 2021-11-04. |
| 保存条件: |
-80°C 6个月; -20°C 1个月,避光,氮气保存 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.175 ml |
5.875 ml |
11.751 ml |
| 5 mM |
0.235 ml |
1.175 ml |
2.35 ml |
| 10 mM |
0.118 ml |
0.588 ml |
1.175 ml |
| 50 mM |
0.024 ml |
0.118 ml |
0.235 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |